Olistico Wealth LLC Has $281,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Olistico Wealth LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 57.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,263 shares of the company’s stock after selling 4,468 shares during the period. Olistico Wealth LLC’s holdings in Novo Nordisk A/S were worth $281,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of NVO. Gabelli Funds LLC increased its stake in Novo Nordisk A/S by 35.7% in the second quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock valued at $6,703,000 after acquiring an additional 12,363 shares during the period. Xponance Inc. boosted its holdings in Novo Nordisk A/S by 27.6% during the second quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after purchasing an additional 576 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after purchasing an additional 689,441 shares during the period. Insigneo Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S by 1.0% in the 2nd quarter. Insigneo Advisory Services LLC now owns 10,693 shares of the company’s stock worth $1,526,000 after buying an additional 108 shares in the last quarter. Finally, Fred Alger Management LLC lifted its position in shares of Novo Nordisk A/S by 38.4% during the 2nd quarter. Fred Alger Management LLC now owns 54,493 shares of the company’s stock worth $7,778,000 after buying an additional 15,129 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $80.59 on Thursday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm’s 50 day moving average is $96.63 and its 200-day moving average is $116.04. The firm has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a PEG ratio of 0.89 and a beta of 0.45.

Analysts Set New Price Targets

Several research analysts have issued reports on NVO shares. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.